After splashing out $27.8bn for Horizon Therapeutics, Amgen is now seeing growth with drugs like Tepezza, Krystexxa, and Uplizna. Credits: Marlon Trottmann/Shutterstock.com Amgen has announced
Adbry targets interleukin-13 (IL-13), a cytokine that drives inflammatory processes that drive symptoms of atopic dermatitis. Credits: Evgeniia Primavera / Shutterstock. Leo Pharma has announced
The latest round of layoffs will see Sage reduce 33% of its total workforce. Credits: Wirestock Creators/Shutterstock.com After a series of mid-stage clinical trial failures,
Stelara is indicated for use in patients with active psoriatic arthritis as well as moderate to severe Crohn’s disease, plaque psoriasis, and active ulcerative colitis.
NP001 is designed to reestablish the balance of pro- and anti-inflammatory processes. Credits: David Herraez Calzada/Shutterstock.com Neuvivo has submitted a New Drug Application (NDA) for
TRIV-573 is a preclinical bispecific antibody designed to target KLK5/7 and interleukin IL-13. Credits: Kmpzzz / Shutterstock. Triveni Bio has secured $115m in a Series
COPD is the sixth approved indication for the interleukin-4 receptor alpha antagonist monoclonal antibody. Credits: Wildflower_macro/Shutterstock.com With the latest nod from the US Food and
VTX3232 is under development for potential uses across several neuroinflammatory and neurodegenerative conditions. Credits: rafapress/Shutterstock.com Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate
Unlike Comirnaty and Spikevax, Kostaive is designed as a sa-mRNA vaccine which should boost a stronger response. Credits: Pormezz/Shutterstock.com CSL and Arcturus Therapeutics’s self-amplifying mRNA
RGX-121 is a gene therapy designed to deliver a functional copy of the IDS gene to the central nervous system via the NAV AAV9 vector.